Join us as we unpack the latest research on glofitamab for mantle cell lymphoma (MCL). We’ll break down the study, compare glofitamab to current treatment options, and explain what this could mean for patients facing relapsed or refractory MCL.HealthTree Resources:News ArticlesWebinarsHealthTree UniversityConnectClinical Trial Finder
This episode explores new preclinical research suggesting that a ketogenic diet may enhance CAR T cell therapy for lymphoma. Join our expert panel as they break down the science, the potential implications, and what’s coming next for a first-in-human clinical trial. HealthTree Resources:Connect - Nutrition & Wellness GroupArticles - Navigating Your HealthEvent - Dietary Guidelines for Cancer Prevention After Treatment Let me know your thoughts on today's episode! Please share them in a comment or reach out anytime at hannah@healthtree.org.
D.R.I.V.E. is a strategic framework for promoting representative enrollment in clinical trials. D.R.I.V.E. addresses safety and efficacy concerns that arise when studies are conducted in populations that do not reflect the different patient groups that treatments are intended to serve. Join Maya Birhiray, medical science liaison, to learn more about this initiative and its importance in clinical trials.HealthTree Resources:HealthTree CureHub and Clinical Trial FinderLymphoma Clinical Trial ArticlesHealthTree Connect GroupsIndy Hematology Education Resources:The DRIVE Initiative website can be accessed here.The DRIVE Score Calculator can be accessed here.Let me know your thoughts on today's episode! Please share them in a comment or reach out anytime at hannah@healthtree.org.
TRANSCEND FL is a global trial assessing the efficacy and safety of the CAR T cell therapy lisocabtagene maraleucel in patients with relapsed or refractory follicular lymphoma. Join Dr. Kamdar, the lead investigator for this trial at University of Colorado Cancer Center, for this podcast to learn more. Feel free to email me with thoughts or questions on this podcast at hannah@healthtree.org. For additional CAR T resources, see below.HealthTree University:What is CAR-T therapy and how is this drug class used to treat follicular lymphoma? What is some of the most promising research being done for follicular lymphoma?What are my options for treating follicular lymphoma? News Articles:Liso-cel CAR T-Cell TherapyCAR T-cell Therapy for Follicular Lymphoma 101 Pages:What are the Treatments for Follicular Lymphoma?
Listen to this podcast with Dr. Carla Casulo and Judith Trotman to hear about some of the most exciting advancements for follicular lymphoma from the 2024 ASH Conference.ASH News Articles:What is ASH? https://healthtree.org/follicular-lymphoma/community/articles/what-is-the-ash-conference-dlbclFL Specialist Insights https://healthtree.org/follicular-lymphoma/community/articles/ash-24-fl-specialists-insights-new-treatmentsBest of ASH 2024: https://healthtree.org/follicular-lymphoma/community/articles/ash-24-the-best-of-it-allASH Videos: https://healthtree.org/blood-cancer/university/courses/klLCY3gkYKWHQDry3bkZ Let me know your thoughts on today's episode! Feel free to email me with questions, comments, or insights at hannah@healthtree.org.
Listen to this pre-recorded podcast to learn from Dr. Ehsan Malek, a hematologist oncologist at Roswell Park, about some of the major breakthroughs in CAR T therapy in 2024 and what is on the horizon in 2025.
Dr. Strati shares about trials happening at MD Anderson for DLBCL and follicular lymphoma. This includes the following: Two completed follicular lymphoma trials: Phase I study of evorpacept and R2 in relapsed indolent B-NHL Phase 2 study of acalabrutinib and R2 in previously untreated indolent B-NHL One ongoing DLBCL trial: Phase 2 study of loncastuximab as consolidation after CART in DLBCL One upcoming DLBCL trial: Phase 2 study of emapalaumab for the treatment of persistent severe cytopenia after CART in DLBCL
Dr. Melani discusses the latest updates from the VVIP, VIPOR, and VIPOR-P studies, which are clinical trials for non-Hodgkin's lymphoma. The goal of these studies is to improve the outcome for patients with relapsed or refractory lymphomas by using targeted therapy combinations. Targeted therapies block specific proteins that cancer cells need to grow and survive. The conversation also discusses these three clinical trials' design and treatment protocols.
Defining and tracking progression/remission in follicular lymphoma patients can be subjective and complicated. In this episode, we are joined by Dr. Juan Pablo Alderuccio. Dr. Alderuccio recently published his research on PET-based biomarkers in lymphoma patients. His research aims to give patients a more accurate knowledge of their lymphoma prognosis. Thank you to our episode sponsor, Regeneron.